GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma
Abstract
G protein-coupled receptor (GPCR) is the most targeted protein family by the FDA-approved drugs. GPCR-kinase 3 (GRK3) is critical for GPCR signaling. Our genomic analysis showed that GRK3 expression correlated with poor prognosis of gastric adenocarcinoma (GAC) patients. However, GRK3’s functions and clinical utility in GAC progression and metastases are unknown.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 23, 2022
- Source ID
- 10.1186/s13046-022-02463-6
Entities
People
- Ailing W. Scott
- Boxuan Yang
- Eun Jeong Cho
- Guoliang Zhang
- Jaffer Ajani
- Jiankang Jin
- Jinbang Xu
- Kevin N Dalby
- Lang Ma
- Lijuan Zhuo
- Longfei Huo
- Matheus Sewastjanow Da Silva
- Melissa Pool Pizzi
- Namita D. Shanbhag
- Shan Shao
- Shumei Song
- Wenliang Li
- Xiaodan Yao
- Yibo Fan
- Ying Wang
- Yuan Li
- Zhenning Wang
Organizations
- National Cancer Institute
- National Institute for Health Care Management